First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study
First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study
复制标题
DOI：
10.1093/annonc/mdq449
复制
发表时间：
2011-04-01
影响因子：
50.5
通讯作者：
de Castro Carpeno, F. J.
中科院分区：
文献类型：
--
作者：
Garcia de Paredes, M. L.;del Moral Gonzalez, F.;de Castro Carpeno, F. J.
背景资料：30%~90%的癌症患者患有疼痛，其中包括神经性疼痛（neuropathic pain，NP），这给癌症患者带来了巨大的负担。因此，它是非常感兴趣的，以确定NP在西班牙的癌症患者的患病率，提高认识的条件，旨在改善癌症NP的管理。患者和方法：1个月的随访前瞻性多中心流行病学研究进行了评估的患病率和管理NP在西班牙肿瘤单位。每个单位的前10名癌症患者诊断为NP的验证DoubletheNeuropathique 4问卷（DN4）被招募。结果：8615筛选患者，2567（30%）患有疼痛。其中，33%的NP根据研究者和19%根据DN4测试。招募了366例患者（平均年龄62.6岁; 61.2%为男性）。在1个月时，转移瘤患者的疼痛减轻程度更大（P <0.01），并依赖于治疗（P <0.05），“羟考酮”显示50.4%的疼痛缓解。DN4仅报告了临床医生诊断的约一半的癌症NP病例。癌症疼痛的药物治疗，包括NP，在转移患者中具有更大的效果，并且似乎取决于所使用的特定治疗。
Background: Thirty percent to ninety percent of cancer patients suffer from pain, including neuropathic pain (NP), which results in great burden for cancer patients. Thus, it was of great interest to determine NP prevalence in cancer patients in Spain, to raise awareness of the condition, and aiming to improve management of cancer NP.Patients and methods: A 1-month follow-up prospective epidemiological multicenter study was conducted to assess prevalence and management of NP in Spanish oncologic units. The first 10 cancer patients at each unit diagnosed with NP by the validated Douleur Neuropathique 4 questionnaire (DN4) were recruited.Results: Of 8615 screened patients, 2567 (30%) suffered from pain. From these, 33% had NP according to investigators and 19% according to DN4 test. Three hundred and sixty-six patients (mean age 62.6 years; 61.2% male) were recruited. Pain decrease at 1 month was greater in patients with metastases (P < 0.01) and depended on treatment (P < 0.05), with 'oxycodone' showing 50.4% pain relief.Conclusions: NP prevalence in cancer pain is 33%. DN4 reports only about half the cancer NP cases diagnosed by clinicians. Pharmaceutical treatment of cancer pain, including NP, has a greater effect in patients with metastases and seems to depend on the specific treatment used.